Singapore markets closed

GSK plc (GSK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
28.66-0.16 (-0.56%)
At close: 04:00PM EDT
28.81 +0.15 (+0.52%)
Pre-market: 08:40AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close28.82
Bid28.76 x 3200
Ask29.13 x 1200
Day's range28.60 - 29.38
52-week range28.47 - 46.97
Avg. volume6,702,607
Market cap57.907B
Beta (5Y monthly)0.26
PE ratio (TTM)11.20
EPS (TTM)2.56
Earnings date01 Feb 2017 - 06 Feb 2017
Forward dividend & yield2.48 (8.46%)
Ex-dividend date19 May 2022
1y target est54.29
  • Reuters

    GSK selects Burberry's Brown as its first female CFO

    (Reuters) -Britain's GSK has appointed its first female chief financial officer, Julie Brown, to succeed Iain Mackay, as the drugmaker focuses on its core pharmaceuticals business. With Emma Walmsley as GSK's chief executive, Brown's appointment also creates a rare, all-female top management at a blue-chip British company and a global pharma major. Brown, who has extensive experience in the health and pharmaceutical industry, will join GSK from luxury fashion brand Burberry, in April and take up the job in May.

  • Zacks

    Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

    The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.

  • Zacks

    Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK

    Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.